ISM6166 / Insilico Medicine - LARVOL DELTA

ISM6166, a novel oral pan-KRAS (ON/OFF) inhibitor discovered with generative AI shows robust anti-tumor activity in solid tumors with KRAS alterations (AACR 2026) - "Additionally, mini-Ames and off-target safety panel profiling indicated no potential risk. Collectively, these findings highlight the potential of this novel molecule as a potent pan-KRAS (ON/OFF) inhibitor for the treatment of solid tumors with KRAS alterations."

Colorectal Cancer • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • DUSP6 • HRAS • KRAS • NRAS

Insilico Medicine…announced the nomination of ISM6166 as a Preclinical Candidate (PCC), a potent, oral pan-KRAS inhibitor designed to treat a broad spectrum of solid tumors, including lung, pancreatic, colorectal, and gastric cancers, generated and optimized using its Chemistry42 platform (Insilico Medicine Press Release) - "In preclinical studies, ISM6166 demonstrated exceptional anti-tumor efficacy. In lung cancer model, oral administration of ISM6166 achieved 86.2% tumor growth inhibition (TGI) and 55.1% tumor regression at 10 mg/kg and 30 mg/kg, respectively. The anti-tumor efficacy was even more pronounced in gastric cancer model, where a 5 mg/kg dose reached 99.5% TGI, and higher doses induced up to 65.8% tumor regression....Insilico is advancing IND-enabling studies for ISM6166 and aims to bring this potential best-in-class candidate into the clinic."

Pipeline update • Preclinical • Colorectal Cancer • Gastric Cancer • Lung Cancer • Pancreatic Cancer • Solid Tumor